A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is exceedingly modest. We plan to winterize the castle, catch up on some reading, and hang with our short person. And what about you? This is a good time to plan a holiday break. You could bolster the economy and shop for wintry sweaters. Or perhaps you might enjoy calculating the impact the tax bill will have on your future. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

The Philippines government plans to sue Sanofi (SNY) and seek a $59 million refund over its dengue fever vaccine in response to a warning the drug could lead to severe infections in some cases, ABS-CBN News tells us. On Monday, regulators suspended use of Dengvaxia after Sanofi said it could worsen symptoms of dengue fever among people who were not infected by the virus before vaccination. Roughly 730,000 schoolchildren have been vaccinated.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Kudos to Pfizer for choosing to manufacture skins in a country with one of the highest rates of HIV/AIDS in the world.

    Good thinking.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy